CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: Clinical, histopathologic, and biochemical findings
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A Caucasian male with Gaucher disease type 3, treated with continuous enzyme therapy (ET) for 11 years, experienced progressive mesenteric and retroperitoneal lymphadenopathy, lung disease, and neurological involvement leading to death at age 12.5 years. Autopsy showed significant pathology of the brain, lymph nodes, and lungs. Liver and spleen glucosylceramide (GluCer) and glucosylsphingosine (GluS) levels were nearly normal and storage cells were cleared. Clusters of macrophages and very elevated GluCer and GluS levels were in the lungs, and brain parenchymal and perivascular regions. Compared to normal brain GluCer (GC 18:0), GluCer species with long fatty acid acyl chains were increased in the patient’s brain. This profile was similar to that in the patient’s lungs, suggesting these lipids were present in brain perivascular macrophages. In the patient’s brain, generalized astrogliosis, and enhanced LC3, Ubiquitin, and Tau signals were identified in the regions surrounding macrophage clusters, indicating proinflammation, altered autophagy, and neurodegeneration. These findings highlight the altered phenotypes resulting from increased longevity due to ET, as well as those in poorly accessible compartments of brain and lung, which manifested progressive disease involvement despite ET.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo
Hickey, W. F., & Kimura, H. (1988) · Science · doi:10.1126/science.3276004 · Cited by 1,466
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citationRitter, M. R., Banin, E., Moreno, S. K., Aguilar, E., Dorrell, M. I., & Friedlander, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29683 · Cited by 275
Dual Roles for Perivascular Macrophages in Immune-to-Brain Signaling
Serrats, J., Schiltz, J. C., García-Bueno, B., van Rooijen, N., Reyes, T. M., & Sawchenko, P. E. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.032 · Cited by 253
Cited by
Nagata, M., Izumi, Y., Ishikawa, E., Kiyotake, R., Doi, R., Iwai, S., Omahdi, Z., Yamaji, T., Miyamoto, T., Bamba, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618133114 · Cited by 172
“C24:1 is abundantly expressed in brain tissue (36, 37) and accumulates greatly in Gaucher disease patients (38).”
BackgroundDaykin, E. C., Ryan, E., & Sidransky, E. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.01.002 · Cited by 77
“While the interstitial lung disease can respond to ERT, the alveolar accumulations of Gaucher cells does not [102].”
BackgroundSun, Y., Liou, B., Chu, Z., Fannin, V., Blackwood, R., Peng, Y., Grabowski, G. A., Davis, H. W., & Qi, X. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102735 · Cited by 39
Self-citationCharacterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
Schiffer, V., Santiago-Mujika, E., Flunkert, S., Schmidt, S., Farcher, M., Loeffler, T., Schilcher, I., Posch, M., Neddens, J., Sun, Y., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227077 · Cited by 11
Self-citation
Metadata
- Authors
- Burrow, T. A., Sun, Y., Prada, C. E., Bailey, L., Zhang, W., Brewer, A., Wu, S. W., Setchell, K. D. R., Witte, D., Cohen, M. B., & Grabowski, G. A.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 114
- Issue
- 2
- Pages
- 233-241
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2041407594
- Cited by
- 70
- References
- 5
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.